[February 27, 2015] |
|
Research and Markets: Pertussis Therapeutics Pipeline Review 2015 - 19 Companies & 25 Drug Profiles
Research and Markets (http://www.researchandmarkets.com/research/kckpjw/pertussis)
has announced the addition of the "Pertussis
- Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic
development for Pertussis, complete with comparative analysis at various
stages, therapeutics assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type, along with
latest updates, and featured news and press releases. It also reviews
key players involved in the therapeutic development for Pertussis and
special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
-
Beijing Minhai Biotechnology Co., Ltd
-
Beijing Tiantan Biological Products Co., Ltd.
-
Bharat Biotech International Limited
-
Biological E. Limited
-
Daiichi Sankyo Company, Limited
-
DBV Techologies S.A.
-
Green Cross Corporation
-
Indian Immunologicals Limited
-
LG Life Sciences, Ltd.
-
NanoBio Corporation
-
Novartis AG
-
Panacea Biotec Limited
-
Sanofi
-
Sanofi Pasteur SA
-
Serum Institute of India Limited
-
Sinovac Biotech Ltd.
-
Synthetic Biologics, Inc.
-
Takeda Pharmaceutical Company Limited
-
Zydus Cadila Healthcare Limited
Drug Profiles
-
(diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2
,3)) vaccine
-
(diphtheria + tetanus + pertussis (acellular) + hepatitis B +
poliomyelitis + haemophilus influenza [serogroup B]) vaccine
-
diphtheria + pertussis + tetanus + hepatitis [serotype B] +
haemophilus influenza [serotype B] vaccine
-
diphtheria + pertussis + tetanus vaccine
-
diphtheria + tetanus + pertussis (acellular) vaccine
-
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae
[type B] + polio (pentavalent) vaccine
-
diphtheria + tetanus + pertussis (whole cell) + hepatitis B +
haemophilus influenzae [type B] + polio (hexavalent) vaccine
-
diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae
[serotype B] vaccine
-
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B +
haemophilus influenzae [serotype B] (pentavalent) vaccine
-
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B +
haemophilus influenzae [serotype B] vaccine
-
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis +
haemophilus influenzae [serotype B] + hepatitis B + meningococcal
[serotype C] (7-valent) vaccine
-
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] +
haemophilus influenzae [type B] (pentavalent) vaccine
-
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] +
poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine
-
diphtheria + tetanus+ pertussis vaccine
-
diptheria + tetanus + pertussis (whole-cell) vaccine
-
DTaP Vaccine
-
GC-3111A
-
pertussis (acellular) vaccine
-
pertussis (whole-cell) vaccine
-
pertussis + hepatitis B vaccine
-
Recombinant BCG - Pertussis Vaccine
-
SYN-005
-
TAK-361S
-
tetanus + diphtheria + pertussis (acellular) vaccine
-
VN-0103
For more information visit http://www.researchandmarkets.com/research/kckpjw/pertussis
[ Back To TMCnet.com's Homepage ]
|